Ferulic acid and berberine, via Sirt1 and AMPK, may act as cell cleansing promoters of healthy longevity

James J DiNicolantonio, Mark F McCarty, Simon Iloki Assanga, Lidianys Lewis Lujan, James H O’Keefe

ABSTRACT

Ferulic acid, a bacterial metabolite of anthocyanins, seems likely to be a primary mediator of the health benefits associated with anthocyanin-rich diets, and has long been employed in Chinese cardiovascular medicine. In rodent studies, it has exerted wide-ranging antioxidant and anti-inflammatory effects, the molecular basis of which remains rather obscure. However, recent studies indicate that physiologically relevant concentrations of ferulic acid can boost expression of Sirt1 at mRNA and protein levels in a range of tissues. Sirt1, a class III deacetylase, functions to detect a paucity of oxidizable substrate, and in response works in various ways to promote cellular survival and healthful longevity. Sirt1 promotes ‘cell cleansing’ and cell survival by boosting autophagy, mitophagy, mitochondrial biogenesis, phase 2 induction of antioxidant enzymes via Nrf2, and DNA repair—while inhibiting NF-κB-driven inflammation, apoptosis, and cellular senescence, and boosting endothelial expression of the protective transcription factor kruppel-like factor 2. A deficit of the latter appears to mediate the endothelial toxicity of the SARS-CoV-2 spike protein. Ferulic acid also enhances the activation of AMP-activated kinase (AMPK) by increasing expression and activity of its activating kinase LKB1—whereas AMPK in turn amplifies Sirt1 activity by promoting induction of nicotinamide phosphoribosyltransferase, rate-limiting for generation of Sirt1’s obligate substrate NAD+. Curiously, AMPK acts by independent mechanisms to potentiate many of the effects mediated by Sirt1. Hence, it is proposed that ferulic acid may exert complementary or synergistic health-promoting effects when used in conjunction with clinically useful AMPK activators, such as the nutraceutical berberine. Additional nutraceuticals which might have potential for amplifying certain protective effects of ferulic acid/berberine are also discussed.

UPREGULATION OF SIRT1 BY FERULIC ACID

Ferulic acid is a bacterial metabolite of anthocyanins that may be a key mediator of the health-protective effects of anthocyanin-rich diets documented in epidemiology and rodent studies. It may also mediate the physiological effects of nutraceuticals such as pycnogenol and elderberry that provide anthocyanins. Various conjugated forms of ferulic acid, of differing degrees of bioavailability, are also found in many natural plant-based foods. In rodents, ferulic acid displays potent anti-inflammatory and antioxidant effects, associated with increased activity of the Nrfl2 transcription factor—driver of the phase 2 antioxidant response—and decreased activity of the pro-inflammatory NF-κB transcription factor. The mechanistic basis of these effects requires further clarification. Clinically, oral or parenteral sodium ferulate has long been employed in Chinese medicine for a range of cardiovascular applications, and a recent Thai clinical study found that, at 1000 mg daily, ferulic acid improves serum lipid profile, reduces markers of oxidative stress, and decreases C reactive protein by about one-third.

An important clue to the basis of ferulic acid’s versatile protective effects may have been provided by recent studies reporting that, in low micromolar concentrations that are readily achievable with oral supplementation and likely by ingestion of anthocyanin-rich diets, ferulic acid upregulates expression of Sirt1 at both the mRNA and protein level. This effect has been demonstrated in chondrocytes, skeletal muscle fibres, testes, neural stem cells and hepatocytes, and hence may be broad in scope. Presumably, ferulic acid either upregulates transcription of the Sirt1 gene or prolongs the half-life of Sirt1 mRNA. Sirt1 is a class III deacetylase that functions to detect a paucity of oxidisable substrate—as during caloric restriction; it responds to this signal by deacetylating a number of target proteins, thereby mediating homeostatic responses to perceived energy deficit. Sirt1 uses NAD+ as an obligate substrate; when the NAD+/NADH ratio is high—as it is when oxidisable fuel is low—Sirt1 activity increases.

The discovery that ferulic acid is a Sirt1 inducer may offer important insight into its effects on Nrf2 and NF-kappaB activities. Sirt1 promotes antioxidant phase 2 induction by...
deacetylating and enhancing the transcriptional activity of Nrf2; this effect likely contributes to the phase 2-inducing activity of ferulic acid, although activation of Erk1/2 is also thought to contribute in this regard. Ferulic acid-mediated induction of Sirt1 would also be expected to combat inflammation by reversing the acetylation of p65 on Lys310 required for optimal transactivation activity of the NF-kappaB complex. There is also evidence that Sirt1 may act more proximally in proinflammatory signalling by suppressing activating phosphorylation and ubiquitination of transforming growth factor-beta activated kinase 1 (TAK1). This presumably reflects the fact that activated Sirt1 binds directly to TAK1. It is not yet clear, however, whether this effect of Sirt1 reflects reversal of an activating acetylation of TAK1. Indeed, certain acetylations of TAK1 may reduce its proinflammatory activity. In any case, Sirt1-mediated inhibition of TAK1 could be expected to prevent TAK1-mediated activation of NF-kappaB and the stress activated MAP kinases p38 and JNK, which collaborate in inducing expression of many proinflammatory cytokines and enzymes. Other intriguing research shows that upregulated expression of the MyD88 coupling factor negates the inhibitory impact of ferulic acid on proinflammatory signalling, for reasons that remain unclear.

**SIRT1 AND AMP-ACTIVATED KINASE COLLABORATE IN PROMOTING AUTOPHAGY, MITOPHAGY AND MITOCHONDRIAL BIOGENESIS**

Of particular interest is the fact that Sirt1 and AMP-activated kinase (AMPK) exert mutually reinforcing effects. Sirt1 deacetylates and thereby enhances the stability and activity of LKB1, an enzyme which activates AMPK via phosphorylation. Conversely, AMPK promotes Sirt1 activity by upregulating expression of nicotinamide phosphoribosyltransferase (NAMPT), which is rate-limiting for re-generation of NAD+, a substrate for Sirt1; NAMPT in the process also lowers cellular levels of nicotinamide, an inhibitor of Sirt1 activity. These considerations suggest that there might a complementary or synergistic interaction between ferulic acid and drug or nutraceuticals that activate AMPK. In this regard, the antidiabetic activities of the drug metformin and the nutraceutical berberine is thought to stem in whole or in part by activation of AMPK. These agents, by modestly boosting cellular AMP levels, enable the activating phosphorylation of AMPK via LKB1. Hence, ferulic acid and metformin or berberine would be expected to exert complementary effects on AMPK activation. In this regard, a synergism between ferulic acid and metformin has been reported in diabetic rats. These considerations encourage the proposal that nutraceutical regimens providing both ferulic acid and berberine might have intriguing potential for health promotion. In particular, it is intriguing to note that Sirt1 and AMPK (which likewise functions as a detector of energy deficit, AMP and ADP enhance its activity) may collaborate in the promotion of autophagy, mitophagy and mitochondrial biogenesis (MB)—processes which jointly promote ‘clean’ cells by disposing of damaged proteins and organelles, while insuring that mitochondria function efficiently and generate only modest levels of oxidants.

Sirt1 and AMPK collaborate in complementary ways in promoting autophagy, which in moderation is thought to promote healthful ageing at the cellular level. Sirt1 acts in this regard by deacetylating various factors which in their deacetylated forms participate in the formation of autophagosomes, as well as via a deacetylation of FOXO1, a transcription factor that enables transcription of the gene coding for Rab7, a G protein essential for autophagosome/lysosome fusion. AMPK promotes mitophagy by increasing expressions of Parkin and Pink1, which tag dysfunctional mitochondria for autophagic destruction. AMPK promotes autophagy by conferring an activating phosphorylation on ULK1 while suppressing the antiautophagic activity of mTORC1.

While Sirt1 and AMPK promote autophagic disposal of ageing mitochondria (mitophagy), they concurrently collaborate to promote MB via activating post-translational modifications of PPAR-γ coactivator-1α (PGC-1α); the latter promotes transcription of a number of genes coding for proteins required for MB. Phosphorylation of PGC-1α by AMPK appears to be a prerequisite for subsequent deacetylation by Sirt1. Sirt1 also promotes MB via its upregulatory impact on Nrf2 activity; this increases expression of nuclear regulatory factor-1 which, via interaction with PGC-1α, transcriptionally upregulates expression of several key proteins required for transcription and replication of mitochondrial DNA. And, finally, Sirt1’s downregulatory impact on NF-kappaB activity likewise aids MB, as NF-kappaB opposes the synthesis and coactivation activity of PGC-1α. MB, coupled with mitophagy, maintains mitochondria in a functionally youthful state, such that they are efficient at ATP generation and less prone to induce oxidative stress. Sirt1, as a detector of inefficient cellular bioenergetics, functions homeostatically to boost production of mitochondria so as to help insure an adequate ATP supply.

By promoting a complex between deacetylated FOXO3a and PGC-1α, as well as by Nrf2 activation, Sirt1 increases expression of manganese-dependent superoxide dismutase and other enzymes that provide antioxidant protection to mitochondria. And Sirt1/AMPK-mediated activation of PGC-1α also decreases mitochondrial oxidant production by inhibiting expression of dynamin-related protein 1, a promoter of mitochondrial fission. Another consequence of PGC-1α activation is increased expression of Sirt3; this acts to minimise mitochondrial oxidant stress, both by modulating nuclear FOXO3a activity, and by acting as an intra-mitochondrial deacetylase. Hence, Sirt1/AMPK activities help to insure that newly synthesised mitochondria remain structurally sound and do not contribute unduly to cellular oxidant load.
Sirt1 also promotes cellular integrity by aiding the efficiency of DNA repair. Sirt1 likewise tends to oppose apoptosis—both via promotion of DNA repair, and by deacetylating and hence inactivating p53. Sirt1 modulation of FOXO3a opposes apoptosis by inhibiting FOXO3a-mediated transcription of the genes coding for the proapoptotic factors Bim and PUMA. Hence, Sirt1 activity aids cell survival under stress by aiding DNA repair and promoting autophagy, while discouraging apoptotic cell death. These effects would tend to suppress tumour initiation, but could aid tumour promotion by aiding the survival of DNA-damaged cells; stimulation of Sirt1 would presumably be contraindicated in the context of cancer chemotherapy. Downregulation of apoptosis would be particularly protective for tissues that do not readily regenerate, such as the heart and central nervous system. The anti-apoptotic effects of Sirt1, coupled with its anti-inflammatory and antioxidant activities, make Sirt1 a promising target for prevention of neurodegenerative disorders and of congestive heart failure.

**SIRT1/AMPK PROMOTE INDUCTION OF KRUPPEL-LIKE FACTOR 2, CRUCIAL FOR HEALTHY ENDOTHELIAL FUNCTION**

The endothelial transcription factor kruppel-like factor 2 (KLF2) is induced by pulsatile shear stress (PSS), and exerts various anti-inflammatory and anti-thrombotic effects, while boosting expression of endothelial nitric oxide (NO) synthase. PSS also enhances the activity of AMPK while increasing the stability of Sirt1; moreover, both AMPK and Sirt1 have been reported to increase KLF2 at the transcriptional level via stimulation of the mitogen-activated protein kinase 5/myocyte enhancing factor 2 (MEF2) signalling pathway. AMPK also phosphorylates and induces nuclear export of HDAC5, which can interact with MEF2 to block its transcriptional activity. And, via deacetylation of NF-kB, Sirt1 may oppose a suppressive effect of NF-kB on transcription of KLF2 and on KLF2-mediated transcription. This findings suggest that a ferulic acid/berberine regimen may collaborate in promoting healthful endothelial function via KLF2 induction. The impact of Sirt1 activity on KLF2 may be pertinent to the use of sodium ferulate in Chinese cardiovascular medicine; analogously, AMPK-mediated KLF2 induction may help to rationalise the favourable influence of metformin treatment on cardiovascular risk in diabetics.

In this regard, it is topical to note that exposure of endothelial cells to serum from patients with COVID-19 or to SARS-CoV-2 spike protein diminishes KLF2 expression, possibly via enhanced proteasomal degradation. Moreover, enhancing KLF2 expression via transfection, bortezomib, or statins was found to suppress the proinflammatory, prothrombotic effects of COVID-19 serum or of spike protein on endothelial cells. Hence, ferulic acid/berberine may have potential for controlling the endotheliopathy associated with COVID-19 or SARS-CoV-2 spike protein exposure (as via mRNA vaccines) by upregulation of KLF2. The upregulatory effect of statins on KLF2 expression has been traced to inhibition of protein prenylation and consequent inhibition of Rho activation. It is reasonable to suspect that modulation of KLF2 is pertinent to the reported favourable impacts of concurrent metformin or statin therapy on COVID-19 prognosis.

**AMPK CAN ALSO BOOST NRF2 ACTIVITY**

In at least certain contexts, AMPK can upregulate Nrf2-mediated induction of phase 2 proteins, in a manner that is independent of Sirt1. In cells which partially rely on insulin receptor substrate-1 (IRS-1) for mitogenic signalling, AMPK can boost Akt activation through inhibition of the mTORC1/p70S6 kinase pathway; the latter kinase confers phosphorylations on IRS-1 that reduce its stability. In turn, via deactivating phosphorylation of glycogen synthase kinase-3b (GSK3b), enhances the stability and nuclear localisation of Nrf2, aiding its transcriptional activity. GSK3b is capable of conferring an activating phosphorylation on Fyn kinase; this causes Fyn kinase to migrate to the nucleus and phosphorylate Nrf2, which induces its export from the nucleus and accelerates its proteasomal degradation. Hence, AMPK mediated Akt activation abrogates the inhibitory impact of GSK3b/Fyn kinase signalling on Nrf2 activity. Other recent studies show that AMPK can directly phosphorylate Nrf2; while these phosphorylations per se do not alter Nrf2 location or stability, they increase the ability of Nrf2 to promote transcription of some (including heme oxygenase-1) but not all Nrf2 target genes. In addition, AMPK-mediated phosphorylation of the transcriptional regulator Bach1 destabilises it, reducing its ability to inhibit transcription of certain Nrf2-responsive genes.

Figure 1Figure 1 summarizes the protective and often complementary effects of Sirt1 and AMPK on cellular processes, transcription factors, and other proteins.

**ANCILLARY NUTRACEUTICALS MAY AMPLIFY THE BENEFICIAL IMPACTS OF FERULIC ACID/BERBERINE**

Melatonin can also cooperate with ferulic acid. Likely acting via its membrane receptors and the Bmal1 transcription factor, melatonin has been reported to upregulate the expression of both Nrf2 and Sirt1. Hence, a regimen of ferulic acid, metformin/berberine and melatonin could be expected to collaborate in promoting strong activation of Sirt1, AMPK and Nrf2—activities linked to health protection and longevity—while downregulating the proinflammatory actions of NF-kappab.

Activation of Nrf2 could be further boosted with nutraceuticals that disrupt Nrf2’s interaction with Keap1, such as lipoic acid and broccoli sprout extracts (which give rise to sulforaphane). Additionally, the spirulina chromophore phycocyanobilin may upregulate...
Nrf2 expression at the transcriptional level, possibly via agonism for the aryl hydrocarbon receptor.\textsuperscript{103–106}

Nicotinamide riboside (NR), now available as a nutraceutical, can be transported into cells and phosphorylated to nicotinamide riboside-5-phosphate, the product of NAMPT. Hence, it, like AMPK activators, has potential to enhance the availability of Sirt1's substrate NAD+.\textsuperscript{107,108} Unfortunately, clinical supplementation studies involving NR intakes of up to 2 g daily have failed to show an impact of such supplementation on skeletal muscle NAD+ levels or indices of mitochondrial function; nor has NR supplementation so far shown an impact on insulin sensitivity in obese, insulin-resistant men.\textsuperscript{109} However, an increase of NAD+ in blood mononuclear cells has been reported in subjects receiving long-term NR supplementation at 500 mg two times a day.\textsuperscript{110} Hence, further clinical exploration of this agent appears warranted.

With respect to Sirt1, both its activity and its expression can be increased by endogenously generated hydrogen sulfide (H$_2$S), which directly sulfhydrates Sirt1.\textsuperscript{111} This might rationalise several reports that supplemental taurine can boost Sirt1 activity; taurine has been shown to enhance expression of the H$_2$S-generating enzymes cystathionine β-synthase and cystathionine γ-lyase in vascular tissues, an effect which might be generalisable to other tissues.\textsuperscript{112–116} Likewise, administration of N-acetylcysteine, a delivery form of the cysteine that serves as substrate for H$_2$S biosynthesis, has been found to increase Sirt1 activity or expression in rodents.\textsuperscript{117,118}

In curious parallel to ferulic acid, urolithin A is a bacterial metabolite of ellagitannins and ellagic acid (found in pomegranates, berries and nuts) thought to mediate the physiological effects of these poorly absorbed phytochemicals.\textsuperscript{119–121} In further parallel, urolithin A has been shown to promote mitophagy and MB in cell cultures and rodents; moreover, a similar effect has now been reported in the skeletal muscle of humans ingesting 500–1000 mg urolithin A daily.\textsuperscript{122–125} In light of these findings, a new report that urolithin A can enhance Sirt1 activity is not surprising.\textsuperscript{126,127} Urolithin A has very recently become available as a nutraceutical, and may have considerable promise for health promotion.\textsuperscript{122}

PGC-1α collaborates with the PPARα transcription factor in promoting transcription of genes coding for various mitochondrial proteins that enable fatty acid oxidation and ketogenesis, such as the carnitine palmitoyltransferases, acyl-CoA oxidase and acetyl-CoA oxidase.\textsuperscript{128,129} The phytochemical antioxidant astaxanthin can function as a PPARα agonist in concentrations achievable via supplementation.\textsuperscript{130,131} This provides a likely explanation for the favourable effects of supplemental astaxanthin on aspects of metabolic syndrome, as reported in obese rodents and humans.\textsuperscript{132–135}

NO, acting via cGMP and enhanced PGC-1α activity, has been found to support MB in skeletal muscle and other tissues.\textsuperscript{136} This may reflect cGMP/PKG1α-mediated activation of p38 MAP kinase via MEK3/6.\textsuperscript{137,138} p38 upregulates PGC-1α expression at the transcriptional level.\textsuperscript{139}
level, and confers multiple phosphorylations on PGC-1α which increase its stability. Hence, agents which support or mimic NO synthase bioactivity may complement Sirt1’s impact on MB. In certain contexts, these may include citrulline, high-dose folate, dietary nitrate and high-dose biotin; the latter can act as a direct activator of soluble guanylate cyclase.

Supplemental carnitine or acylcarnitine has been shown to enhance MB in skeletal muscle, brain and liver of ageing rodents—an effect associated with increased expression of PGC-1α at the mRNA and protein level. This effect is not seen in younger animals, likely because supplemental carnitine has little effect on their tissue levels of carnitine. In contrast, carnitine levels in these tissues decline with age—likely owing to decreased expression of the carnitine transporter OCTN2—and carnitine supplementation restores more youthful tissue carnitine levels in old rodents.

It has been suggested that the impact of supplemental carnitine on PGC-1α in ageing rodents reflect the ability of carnitine to moderately inhibit type 1 histone deacetylase activity in physiological tissue concentrations; the type 1 histone deacetylase HDAC3 activity has been reported to suppress PGC-1α expression at the transcriptional level. A clinical correlate of these findings is that, in elderly subjects complaining of ‘tiredness’, carnitine supplementation has been found in double-blind studies to boost perceived physical and mental energy.

Because a ferulic acid/berberine regimen boosts induction of antioxidant enzymes via Nrf2 and FOXO transcription factors, while concurrently controlling mitochondrial oxidant production by stimulating mitophagy/MB, it can be viewed as a fruitful strategy for control of oxidative stress. Ancillary nutraceutical strategies in that regard include astaxanthin—which protects the structural integrity of the mitochondrial electron transport chain from oxidant damage; phycocyanobilin—a spirulina chromophore which mimics free bilirubin in inhibiting certain forms of NADPH oxidase; citrulline and high-dose folate—which promote recoupling of NO synthase in certain contexts; and N-acetylcysteine, which can amplify glutathione synthesis.

It should also be noted that exercise training can boost MB in the trained muscles. p38, along with calcium/calmodulin-dependent kinase II (CaMKII), upregulate PGC-1α activity and MB in exercised skeletal muscle. Oxidant production, primarily from xanthine oxidase, drives exercise-induced p38 activation, whereas activation of CaMKII is mediated by increased cytosolic free calcium.

**CONCLUSION**

In summation, combined supplementation with ferulic acid and berberine, via mutually reinforcing activations of Sirt1 and AMPK, has the potential to promote a number of processes that help to keep cells ‘clean’ and properly functional—autophagy, mitophagy, MB, DNA repair, phase 2 induction—while aiding survival of non-renewable cells via suppression of apoptosis, senescence and NF-κB-driven inflammation. Exploration of this strategy in multiple rodent models of pathologies would be appropriate. Clinically, dose schedules of ferulic acid and of berberine that have shown physiological effects are in the range of 250–500 mg two times a day, and 500 mg, two/three times a day, respectively.

**Contributors** All authors contributed to the final manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** JJD is Director of Scientific Affairs at Advanced Ingredients for Dietary Products. MM is coinventor and co-owner on a US patent for nutraceutical uses of phycocyanobilin oligopeptides derived from spirulina. SA and LMLL have no conflicts. JOK is an owner of a nutraceutical company.

**Patient consent for publication** Not applicable.

**Ethics approval** Not applicable.

**Provenance and peer review** Not commissioned; internally peer reviewed.

**Data availability statement** No data are available.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iDs**

James J DiNicolantonio http://orcid.org/0000-0002-7888-1528

James H O’Keefe http://orcid.org/0000-0002-3376-5822

REFERENCES

1. McCarty MF, Assanga SBI. Ferulic acid may target MyD88-mediated pro-inflammatory signaling - Implications for the health protection afforded by whole grains, anthocyanins, and coffee. Med Hypotheses 2018;118:114–20.

2. Virgili F, Pagana G, Bourle L, et al. Ferulic acid excretion as a marker of consumption of a French maritime pine (Pinus maritima) bark extract. Free Radic Biol Med 2000;28:1249–56.

3. Farrell NJ, Norris GH, Ryan J, et al. Black elderberry extract attenuates inflammation and metabolic dysfunction in diet-induced obese mice. Br J Nutr 2015;114:1213–31.

4. Zhang X-X, Zhao D-S, Wang J, et al. The treatment of cardiovascular diseases: a review of ferulic acid and its derivatives. Pharmacazie 2021;76:55–60.

5. Bumrungpert A, Lilitchan S, Tuntippopiat S, et al. Ferulic acid supplementation improves lipid profiles, oxidative stress, and inflammatory status in hyperlipidemic subjects: a randomized, double-blind, placebo-controlled clinical trial. Nutrients 2018;10. doi:10.3390/nu10060713. [Epub ahead of print: 02 Jun 2018].

6. El-Mesallamy HO, Gawish RA, Sallam A-AM, et al. Ferulic acid protects against radiation-induced testicular damage in male rats: impact on SIRT1 and PARP1. Environ Sci Pollut Res Int 2018;25:6218–27.

7. Moghadam FH, Mestah-Ardakani M, Naar-Esfahi MH. Ferulic acid exerts concentration-dependent anti-apoptotic and neuronal differentiation-inducing effects in PC12 and mouse neural stem cells. Eur J Pharmacol 2018;841:104–12.

8. Hou T, Zhang L, Yang X. Ferulic acid, a natural polyphenol, protects against osteoporosis by activating SIRT1 and NF-κB in neonatal rats with glucocorticoid-induced osteoporosis. Biomed Pharmacother 2019;120:109205.

9. Xu T, Song Q, Zhou L, et al. Ferulic acid alleviates lipotoxicity-induced hepatocellular death through the SIRT1-regulated autophagy pathway and independently of AMPK and Akt in AML-12 hepatocytes. Nutr Metab 2021;18:13.

10. Wang Y, Chen X, Huang Z, et al. Effects of dietary ferulic acid supplementation on growth performance and skeletal muscle fiber type conversion in weaned piglets. J Sci Food Agric 2021;101:5116–23.
Du K, Fang X, Li Z. Ferulic acid suppresses interleukin-1β-induced degeneration of chondrocytes isolated from patients with osteoarthritis through the SIRT1/AMPK/PGC-1α signaling pathway. *Immun Inflamm Dis* 2021;9:710–20.

Tang BL. SIRT1’s systemic protective roles and its promise as a target in antiaging medicine. *Trends in Endocrinology & Metabolism* 2011;17:276–84.

Ding Y-W, Zhao G-J, Li X-L, et al. SIRT1 exerts protective effects against paraquat-induced injury in mouse type II alveolar epithelial cells by deacetylating Nrfl2 in vitro. *Int J Mol Med* 2016;37:1049–58.

Hu D, Zhang L, Jiang R, et al. Nicotinic acid against acetylaminophen-induced hepatotoxicity via SIRT1/Nrf2 antioxidative pathway in mice. *J Nutr Sci Vitamino* 2021;67:145–52.

Salminen A, Kauppinen A, Suuronen T, et al. SIRT1 longevity factor suppresses NF-kB-mediated immune responses: regulation of aging via NF-kappaB acetylation? *Bioessays* 2008;30:939–42.

Mao ZC, Hong Q, Wang YG, et al. Ferulic acid induces heme oxygenase-1 via activation of ERK and Nrf2. *Drug Discov Ther* 2011;5:299–305.

Cataldo S, Piacioli F, Miceli F, et al. Ferulic acid regulates the Nrf2/Heme oxygenase-1 system and counters Trimethylin-Induced neuronal damage in the human neuroblastoma cell line SH-SYSY. *Front Pharmacol* 2016;6:305.

Koh E-J, Kim K-J, Seo Y-J, et al. Modulation of HO-1 by ferulic acid attenuates acetyl-pyocyanine differentiation in ST3-L1 cells. *Molecules* 2017;22, doi:10.3390/molecules22050745. [Epub ahead of print: 05 May 2017].

Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappab-dependent transcription and cell survival by the SIRT1 deacetylase. *Embo J* 2004;23:3663–80.

Yang H, Hu J, Chen YJ, et al. Role of SIRT1 in innate immune mechanisms against Mycobacterium tuberculosis via the inhibition of TAK1 activation. *Arch Biochem Biophys* 2019;667:49–58.

Paquette N, Conlon J, Sweet C, et al. Serine/Threonine acetylation of TGFβ1-activated kinase (TAK1) by Vernalia pestis Yap1 inhibits innate immune signaling. *Proc Natl Acad Sci U S A* 2012;109:12710–5.

Lan F, Caccidejo JM, Ruderman N, et al. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. *J Biol Chem* 2008;283:27628–35.

Fuclo M, Cen Y, Zhao P, et al. Glucose restriction inhibits skeletal muscle myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of NAMPT. *Dev Cell* 2008;14:661–73.

Costford SA, Bajpeyi S, Pasarica M, et al. Skeletal muscle NAMPT is induced by exercise in humans. *Am J Physiol Endocrinol Metab* 2010;298:E117–26.

Revollo JR, Grimm AA, Imai S-ichi. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. *J Biol Chem* 2004;279:50754–63.

Skokowa J, Lan D, Thakur BK, et al. NAMPT is essential for the regulation of fusion and fission leading to mitophagy triggered by a signaling network of Sirt1-Foxo3-PINK1-PARKIN. *Oxid Med Cell Longev* 2014;2014:1–13.

Russell RC, Yuan H-X, Guan K-L. Autophagy regulation by nutrient signaling. *Cell Res* 2012;22:44–57.

Zhao M, Kilonsky DJ. Ampk-Dependent phosphorylation of ULK1 induces autophagy. *Cell Metab* 2011;13:119–20.

Kim J, Guan K-L. Regulation of the autophagy initiating kinase ULK1 by nutrients: roles of mTORC1 and AMPK. *Cell Cycle* 2011;10:1337–8.

Tang BL, Sirt1 and the mitochondria. *Mol Cells* 2016;39:87–95.

Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. *Biochim Biophys Acta* 2011;1813:1269–76.

Fernandez-Marcos PJ, Auwerx J. Regulation of PGC-1α, a nodal regulator of mitochondrial biogenesis. *Am J Clin Nutr* 2011;93:848S–90.

Cantó C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. *Nature* 2009;458:506–10.

Plantadosi CA, Carraway MS, Babiak A, et al. Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1. *Circ Res* 2008;103:1232–40.

Glezner J, Vercauteren K, Scarpulla R. Control of mitochondrial transcription specificity factors (TFB1M and TFB2M) by nuclear respiratory factors (NRF-1 and Nrf-2) and PGC-1 family coactivators. *Mol Cell Bio* 2005;25:1354–66.

Remels AHV, Gosker HR, Bakker J, et al. Regulation of skeletal muscle oxidative phenotype by classical NF-kB signaling. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease* 2013;1823:1312–23.

Alvarez-Guardia D, Palomer X, Coll T, et al. The p65 subunit of NF-κB binds to PGC-1α, linking inflammation and metabolic disturbances in cardiac cells. *Cardiov Res* 2010;87:449–58.

Olmos Y, Sánchez-Gómez FJ, Wild B, et al. SIRT1 regulation of antioxidant genes is dependent on the formation of a Foxo3α/PGC-1α complex. *Antioxid Redox Signal* 2013;19:1507–21.

Ding M, Feng N, Tang D, et al. Melatonin prevents Drp1-mediated mitochondrial fission in diabetic hearts through SIRT1-PCG1α pathway. *J Pineal Res* 2018;65:e12491.

Yu L, Gong B, Duan W, et al. Melatonin ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic rats by preserving mitochondrial function: role of AMPK-PGC-1α-SIRT3 signaling. *Sci Rep* 2017;7:41337.

Lombard DB, Zwaans BM. Sirt3: as simple as it seems? *Gerontology* 2014;60:56–64.

Chen J-X, Yang L, Sun L, et al. Sirtuin 3 ameliorates lung tumorigenicity and importantly downregulates type II alveolar epithelial cell function by enhancing the Foxo3a-Dependent antioxidant defense mechanism. *Stem Cells Dev* 2021;30:843–55.

Lagunas-Rangel FA. Current role of mammalian sirtuins in DNA repair. *DNA Repair* 2019;80:85–92.

Lee SH, Lee J-H, Lee H-Y, et al. Sirtuin signaling in cellular senescence and aging. *BMB Rep* 2019;52:24–34.

Vaziri H, Dessain SK, Eaton EN, et al. H3R2SIRT1 functions as an emerging beneficial roles of sirtuins in heart failure. *Basic Res Cardiol* 2012;107:273.

Giannakou ME, Partridge L. The interaction between Foxo and Sirt1: tipping the balance towards survival. *Trends Cell Biol* 2004;14:408–12.

Chen L, Li S, Zhu J, et al. Mangiferin prevents myocardial infarction-induced apoptosis and heart failure in mice by activating the Sirt1/Foxo3a pathway. *J Cell Mol Med* 2021;25:2944–55.

Zhao X, Liu Y, Zhu G, et al. Sirt1 downregulation mediated manganese-induced neuronal apoptosis through activation of Foxo3α-Bim/PUMA axis. *Sci Total Environ* 2019;646:1047–55.

García-Peterson LM, Li X. Trending topics of SIRT1 in tumorigenicity. *Biochim Biophys Acta Gen Subj* 2021;1865:129952.

Jiao F, Gong Z. The beneficial roles of SIRT1 in Neuroinflammatory-Related diseases. *Oxid Med Cell Longev* 2020;2020:1–19.

Tanno M, Kuno A, Horio Y, et al. Emerging beneficial roles of sirtuins in heart failure. *Basic Res Cardiol* 2012;107:273.

SenBanerjee S, Lin Z, Atkins GB, et al. Klf2 is a novel transcriptional regulator of endothelial proinflammatory activation. *J Exp Med* 2004;199:1305–15.
DiNicolantonio JJ, et al. Open Heart 2022;9:e001801. doi:10.1136/openhrt-2021-001801
Sun Q, Hu H, Wang W, et al. Taurine attenuates amyloid β 1-42-induced mitochondrial dysfunction by activating of SIRT1 in SK-N-SH cells. *Biochem Biophys Res Commun* 2014;447:485–9.

Abd Elwahab AH, Ramadan BK, Schaalau MF, et al. A novel role of SIRT1/ FGF-21 in taurine protection against cafeteria diet-induced metabolic syndrome in rats. *Cell Physiol Biochem* 2017;43:544–59.

Liu J, Ai Y, Niu X, et al. Taurine protects against cardiac dysfunction induced by pressure overload through SIRT1-p53 activation. *Chem Biol Interact* 2020;317:108972.

Sun Q, Wang B, Li Y, et al. Taurine supplementation lowers blood pressure and improves vascular function in prehypertension: randomized, double-blind, placebo-controlled study. *Hypertension* 2016;67:541–9.

Guizmo DM, Freitas IN, Victoria JA, et al. Taurine treatment reverses protein malnutrition-induced endothelial dysfunction of the pancreatic vasculature: the role of hydrogen sulfide. *Metabolism* 2021;116:154701.

Yang L, Duan Z, Lu X, et al. N-acetylcysteine ameliorates the PM2.5-induced oxidative stress by regulating SIRT1 in rats. *Environ Toxicol Pharmacol* 2018;57:70–5.

Li C, Xie N, Li Y, et al. N-Acetylcysteine ameliorates cisplatin-induced renal senescence and renal interstitial fibrosis through Sirtuin1 activation and p53 deacetylation. *Free Radic Biol Med* 2019;130:512–27.

Cerda B, Periago P, Espin JC, et al. Identification of urtiolin as a metabolite produced by human colon microflora from ellagic acid and related compounds. *J Agric Food Chem* 2005;53:5571–8.

Seeram NP, Henning SM, Zhang Y, et al. Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. *J Nutr* 2006;136:2481–5.

Istas G, Feliciano RP, Weber T, et al. Plasma urolithin metabolites correlate with improvements in endothelial function after red raspberry consumption: a double-blind randomized controlled trial. *Arch Biochem Biophys* 2018;651:43–51.

D’Amico D, Andreux PA, Valdés P, et al. Impact of the natural compound urtiolin A on health, disease, and aging. *Trends Mol Med* 2021;27:687–99.

Ryu D, Mouchiroud L, Andreux PA, et al. Urtiolin induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. *Nat Med* 2016;22:879–88.

Lin J, Zhuo J, Zheng X, et al. Urtiolin A-induced mitophagy suppresses apoptosis and attenuates intervertebral disc degeneration via the AMPK signaling pathway. *Free Radic Biol Med* 2020;150:109–19.

Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urtiolin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. *Nat Metab* 2018;1:595–603.

Velagapudi R, Lepiarz I, El-Bakouh A, et al. Induction of autophagy and activation of SIRT-1 deacetylation mechanisms mediate neuroprotection by the pomegranate metabolite urtiolin A in BV2 microglia and differentiated 3D human neural progenitor cells. *Mol Nutr Food Res* 2019;63:1801237.

Ghosh N, Das A, Biswas N, et al. Urtiolin A augments angiogenic pathways in skeletal muscle by bolstering NAD+ and SIRT1. *Sci Rep* 2020;10:20184.

Kersten S. Integrated physiology and systems biology of PPARY and related compounds. *J Nutr Biochem* 2016;28:9–18.

Costell M, O'Connor J, Grisolla S. Age-Dependent decrease of carnitine content in muscle of mice and humans. *Biochem Biophys Res Commun* 1989;161:1153–43.

Costell M, Grisolla S. Effect of carnitine feeding on the levels of heart and skeletal muscle carnitine of elderly mice. *FEBS Lett* 1993;315:43–6.

Karic H, Lohninger A, Laschan C, et al. Downregulation of carnitine acytransferases and organic cation transporter OCTN2 in mononuclear cells in healthy elderly and patients with myelodysplastic syndromes. *J Mol Med* 2003;81:435–42.

McCarthy MJ, D’Nicolantonio JJ, et al. Oxidative stress and peroxisome proliferator-activated receptor-γ coactivator-1alpha (PGC-1α) require nitric oxide-, insulin-, and α-lipoic acid for expression. *FASEB J* 2010;24:1326–38.

McCarthy MD, Scapagnini G, et al. The natural carotenoid astaxanthin, a peroxisome proliferator-activated receptor γ coactivator-1alpha (PGC-1α) activator urolithin A is safe and induces a molecular signature of autophagy and activation of SIRT-1 in 293T fibroblasts *Rejuvenation Res* 2020;23:1076–91.

McCarty MF. Asymmetric dimethylarginine is a well established mediating risk factor for cardiovascular morbidity and Mortality-Should patients with elevated levels be supplemented with citrulline? *Healthcare* 2016;4: doi:10.3390/healthcare4030040. [Epub ahead of print: 08 07 2016].

Siu KL, Miao XN, Cai H. Recoupling of eNOS with folic acid prevents abnormally elevated birefringence formation in angiotensin II-infused apolipoprotein E null mice. *PLoS One* 2014;9:e88899.

Chalupsky K, Kračun D, Kanchev I, et al. Folic acid promotes recycling of tetrahydrobiopterin and protects against hypoxia-induced pulmonary hypertension by Recoupling endothelial nitric oxide synthase. *Antioxid Redox Signal* 2015;23:1076–91.

Gadaletta MN, Petruzella V, Renis M, et al. Reduced transcription of mitochondrial DNA in the senescent rat, tissue dependence and effect of L-carnitine. *Eur J Biochem* 1990;187:501–6.

Pesce V, Fracasso F, Cassano P, et al. Acetyl-L-Carnitine supplementation to old rats partially reverses the partly impaired mitochondrial decay of soleus muscle by activating peroxisome proliferator-activated receptor gamma coactivator-1alpha-dependent mitochondrial biogenesis. *Rejuvenation Res* 2010;13:148–51.

Pesce V, Nicassio L, Fracasso F, et al. Acetyl-L-Carnitine activates the peroxisome proliferator-activated receptor-γ coactivators PGC-1α/PGC-1β-dependent signaling cascade of mitochondrial biogenesis and decreases the oxidized peroxiredoxins content in old rat liver. *Rejuvenation Res* 2012;15:136–9.

Nicassio L, Fracasso F, Sirago G, et al. Dietary supplementation with acetyl-L-carnitine counteracts age-related alterations of mitochondrial biogenesis, dynamics and antioxidant defenses in brain of old rats. *Exp Gerontol* 2017;98:99–109.

Malaguarnera M, Di Mauro A, Gargante PM, et al. Alc treatment in elderly patients with fatigue. *South Med J* 2006;99:315–6.

Malaguarnera M, Di Mauro A, Gargante PM, et al. HDac inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo. *PLoS One* 2012;7:e49062.

Galmozzi A, Mitro N, Ferrara A, et al. Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue. *Diabetes* 2013;62:732–42.

Malaguarnera M, Di Mauro A, Gargante PM, et al. L-Carnitine reduces severity of physical and mental fatigue and improves daily activities in the elderly. *South Med J* 2006;99:315–6.

Malaguarnera M, Gargante MP, Cristaldi E. Alc treatment in elderly patients with fatigue. *Arch Gerontol Geriatr* 2008;46:181–90.

Malaguarnera M, Cammalleri L, Gargante MP, et al. L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial. *Am J Clin Nutr* 2007;86:1738–44.

Krestinin O, Baburina Y, Krestinin R, et al. Astaxanthin prevents mitochondrial impairment induced by isoproterenol in isolated rat heart mitochondria. *Antioxidants* 2020;9: doi:10.3390/antiox9030262. [Epub ahead of print: 23 03 2020].
157 McCarty MF. Clinical potential of Spirulina as a source of phycocyanobilin. J Med Food 2007;10:566–70.
158 Zheng J, Inoguchi T, Sasaki S, et al. Phycocyanin and phycocyanobilin from Spirulina platensis protect against diabetic nephropathy by inhibiting oxidative stress. Am J Physiol Regul Integr Comp Physiol 2013;304:R110–20.
159 Gao L, Siu KL, Chalupsky K, et al. Role of uncoupled endothelial nitric oxide synthase in abdominal aortic aneurysm formation: treatment with folic acid. Hypertension 2012;59:158–66.
160 Atkuri KR, Mantovani JJ, Herzenberg LA, et al. N-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 2007;7:355–9.

161 Dodd S, Dean O, Copolov DL, et al. N-Acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 2008;8:1955–62.
162 Akimoto T, Pohnert SC, Li P, et al. Exercise stimulates PGC-1alpha transcription in skeletal muscle through activation of the p38 MAPK pathway. J Biol Chem 2005;280:19987–93.
163 Zhang Y, Uguccioni G, Ljubicic V, et al. Multiple signaling pathways regulate contractile activity-mediated PGC-1α gene expression and activity in skeletal muscle cells. Physiol Rep 2014;2. doi:10.14814/phy2.12008. [Epub ahead of print: 19 05 2014].
164 Kang C, O’Moore KM, Dickman JR, et al. Exercise activation of muscle peroxisome proliferator-activated receptor-gamma coactivator-1alpha signaling is redox sensitive. Free Radic Biol Med 2009;47:1394–400.